VEGFA and renal cell carcinoma: Current clinical strategies for RCC commonly involve combining anti-angiogenic agents, such as VEGF or VEGF receptor blocking agents or tyrosine kinase inhibitors, with immune checkpoint blockade, which has demonstrated clinical benefit.23